Nonanthracycline anticancer drugs can cause a wide spectrum of cardiac and cardiovascular adverse effects, ranging from subclinical abnormalities to life-threatening sequelae.
Anthracyclines are a well-known cause of cardiotoxicity, but a number of other drugs used to treat cancer can also result in cardiac and cardiovascular adverse effects. Cardiotoxicity can result in the alteration of cardiac rhythm, changes in blood pressure and ischemia, and can also alter the ability of the heart to contract and/or relax. The clinical spectrum of these toxicities can range from subclinical abnormalities to catastrophic life-threatening, and sometimes fatal, sequelae. These events may occur acutely or may only become apparent months or years following completion of oncological treatment. Ischemia and rhythm abnormalities are treated symptomatically in most cases. Knowledge of these toxicities can aid clinicians to choose the optimal and least toxic regimen suitable for an individual patient.
Jones et al. (Fri,) conducted a review in Cancer / Cardiotoxicity. Nonanthracycline anticancer drugs was evaluated. Nonanthracycline anticancer drugs can cause a wide spectrum of cardiac and cardiovascular adverse effects, ranging from subclinical abnormalities to life-threatening sequelae.